glp-1 eligibility qualifications for meds GLP-1 RAs hold promise for pediatric obesity, MASLD; barriers persist altRx GLP-1 Review 2026: Updated

Native GLP-1 is degraded in under 2 minutes by the enzyme DPP-4

RCT SCALE Study - Liraglutide vs Placebo for Weight Loss in Overweight Nondiabetic Adults, NEJM (2015) [PubMed abstract] The SCALE study enrolled 3731 overweight adults who did not have diabetes Main inclusion criteria BMI 30

Maintaining Weight Loss Progress One common concern is whether illness will derail weight loss progress

Participants with baseline retinopathy who achieved substantial A1c reductions within the first 16 weeks of treatment faced the highest risk of progression

High values of serum amylase and lipase indicate pancreatic inflammation

Suitable for use alongside GLP-1 receptor agonist medications (consult your doctor)